Recent research findings indicate that Th2-associated immune cells and cytokines play an important role in the pathogenesis of prurigo nodularis (PN). This is the therapeutic target of the two biologics, which are seen as a beacon of hope for severely affected patients in particular. Dupilumab blocks the effect of IL-4 and IL-13 and was recently granted an indication extension for PN by Swissmedic. Nemolizumab, also a biologic, is directed against IL-31 and has already been approved in some other countries for the treatment of PN.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- DERMATOLOGIE PRAXIS
